213250-61-4

Basic information

• Product Name: Cyclohexanone, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylene-, (3R,5R)-
• CAS NO: 213250-61-4
• Molecular Formula: C19H38O3Si2
• Molecular Weight: 370.68
• Mol File: 213250-61-4.mol
• Article Data: 25

Chemical Properties

• CAS DataBase Reference: Cyclohexanone, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylene-, (3R,5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanone, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylene-, (3R,5R)-(213250-61-4)
• EPA Substance Registry System: Cyclohexanone, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylene-, (3R,5R)-(213250-61-4)

Safety Data

• Hazardous Substances Data: 213250-61-4(Hazardous Substances Data)

Upstream product

• 766529-88-8 (1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 77-95-2 D-(-)-quinic acid 
• 1349703-62-3 (R)-7-[(tert-butyldimethylsilyl)oxy]-8-methylene-1,4-dioxa-spiro[4.5]decane 
• 1349703-60-1 (R)-7-[(tert-butyldimethylsilyl)oxy]-1,4-dioxa-spiro[4.5]decan-8-one 
• 1349703-70-3 (7R,9R)-7,9-bis-[(tert-butyldimethylsilyl)oxy]-8-methylene-1,4-dioxa-spiro[4.5]decane 
• 1349703-64-5 (7R,9R)-9-[(tert-butyldimethylsilyl)oxy]-8-methylene-1,4-dioxa-spiro[4.5]decan-7-ol 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 851764-31-3 (R)-4-hydroxy-1,4-dioxa-spiro[4.5]decan-8-one 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 213250-58-9 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-oxocyclohexanecarboxylic acid methyl ester 

Downstream Products

• 213250-62-5 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate 
• 852658-76-5 C₃₆H₆₆O₂Si₂ 
• 852658-61-8 C₃₄H₆₂O₂Si₂ 
• 852658-66-3 C₃₅H₆₄O₂Si₂ 
• 852658-46-9 2-Methylene-(20S)-19-nor-1alpha-hydroxy-trishomopregnacalciferol 
• 852658-44-7 (20R)-1alpha-Hydroxy-2-methylene-19-nor-bishomopregnacalciferol 
• 852658-50-5 2-methylene-19,21-dinor-1α-hydroxybishomopregnacalciferol 
• 213250-69-2 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 213250-65-8 (1R,3R,7E,17β)-1,3-bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylidene-17-{6-methyl-6-[(triethylsilyl)oxy]heptan-2-yl}-9,10-secoestra-5,7-diene 

Relevant articles and documents

Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects

We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3αS,7αS)-1-((R)-1-((S)-3-hydroxy-2, 3-dimethylbutoxy)ethyl)-7α-methyldihydro-1H-inden-4(2H,5H,6H,7H,7αH) -ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation o

VITAMIN D RECEPTOR AGONISTS AND USES THEREOF

Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen, or a pharmaceutically acceptable salt